Management of the coinfected patient: Human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C

American Journal of the Medical Sciences

Volumn 328, Issue 1, 2004, Pages 26-36

  Murphy, Mary J ^a,b   Wilcox, Ronald D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HIV Outpatient Program   (United States)

Author keywords

Adefovir; Hepatitis B; Hepatitis C; HIV; Pegylated interferon

Indexed keywords

ADEFOVIR; EMTRICITABINE; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; TENOFOVIR;

COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MORTALITY; NEPHROTOXICITY; PRACTICE GUIDELINE; REVIEW; SAFE SEX; SCREENING; SIDE EFFECT; VACCINATION; VIRUS TRANSMISSION;

EID: 3242737588     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200407000-00005     Document Type: Article

References (40)

1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
2. Martin-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-71.
3. Lok A, Heattcote E, Hoofnagle J. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 12:1828-53.
4. Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients for hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998;17:6-13.
5. Thio CL, Seaburg EC, Skolasky RL, et al. HIV-1, hepatitis B virus, and the risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002;360: 1921-6.
6. Chung RT, Kim AY, Polasky B. HIV/hepatitis B and C coinfection: pathogenic interactions, natural history and therapy. Antivir Chem Chemother 2001;12(suppl 1):73-91, 2001.
7. Gilson RJC, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effect on the natural history of infection. AIDS 1997;11:597-606.
8. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
9. Biggar RJ, Goedert JJ, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987;316:630-1.
10. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine infections augments anti-HBs response rates in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18:1161-5.
11. Thio CL. Hepatitis B in the human immunodeficiency virus infected patient: epidemiology, natural history and treatment. Semin Liver Dis 2003;23:125-36.
12. Wong DK, Cheung AM, O'Rourke K, et al. Effect of α-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. Ann Intern Med 1993;119:312-32.
13. Perrillo RP, Schiff ER, Davis GL, et al. A randomized controlled trial of interferon α-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
14. Cooksley WGE, Piratvisuth T, Lee SD, et al. Peg interferon α 2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
15. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339: 61-8.
16. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
17. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;1302-6.
18. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of patients with Hbe antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
19. Xiong S, Yabg H, Westland C, et al. Resistance surveillance of HBeAG-positive chronic hepatitis B patients treated for two years with adefovir dipivoxil. 11th International Symposium on Viral Hepatitis and Liver Disease, 2003, Abstract 779.
20. Nunez M, Perez-Olmeda M, Diaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine. AIDS 2002;16:2352-4.
21. Gish R, Leung NW, Wang C, et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients given once-daily oral emtricitabine for 2 years. Hepatology 2002;36:372A.
22. Alter MJ, Margolis HS, Krawczyski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
23. Nadler JP, Volberding PA. The emergence of hepatitis C as a major pathogen in HIV-infected persons. In: Expert perspectives II: Strategies for the management of HIV/HVC coinfection. Secaucus, NJ: Projects in Knowledge; 2002. p. 1-3.
24. US Public Health Service (USPHS) and Infectious Disease Society of America (IDSA). 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Available at http://www.aidsinfo.nih.gov/guidelines/op_infections/OL_112801.pdf. Accessed September 5, 2003.
25. Berggren RE, Sulkowski MS, Torbenson MS. New patient assessment. In: Expert perspectives II: Strategies for the management of HIV/HCV coinfection. Secaucus, NJ: Projects in Knowledge; 2002. p. 4-7.
26. Fanning L, Kenny E, Sheehan M, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999;29:904-7.
27. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
28. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33: 562-9.
29. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47(RR-19):1-39.
30. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J Infect Dis 1998;177: 1480-6.
31. Jain MK, Skiest DJ, Cloud JW, et al. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003;36:1030-8.
32. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356: 1800-5.
33. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 2002;16:1915-23.
34. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
35. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
36. Phillips E. A retrospective cohort study of liver toxicity in hepatitis B and C HIV co-infected patients in the HIV Ontario Observational Database (HOOD). Presented July 2003 at the International AIDS Society Conference, Paris, France.
37. Price P, Mathiot N, Krueger R, et al. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001;22: 279-87.
38. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-1.
39. Bonacicni M. Management issues in patients coinfected with hepatitis C virus and HIV. AIDS Reader 2002;12:19-26.
40. Perrone C, Carrat F, Bani Sadr F, et al, for the ANRS HC02 Study Group. RIBAVIC Trial (ANRS HC02): a controlled randomized trial of pegylated interferon α-2b plus ribavirin vs interferon α-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV coinfected patients: preliminary results [abstract LbOr16]. Presented at the AIDS 2002 Barcelona XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain.